Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 26

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 26
---
 the litigation could subject us to significant liabilities to such third party, require us
to seek a license for the disputed rights from such third party, and/or require us to cease use of the technology. Further, our breach
of an existing license or failure to obtain a license to technology required to commercialize our products may seriously harm our business.
We also may need to commence litigation to enforce any patents issued to us or to determine the scope and validity of third party proprietary
rights. Litigation would not only involve substantial costs but would also involve substantial time commitments on the part of our key
executives and research and development personnel.

In March 2015, we licensed intellectual property
related to CAR T technology from COH. In May 2023, we announced a series of changes resulting from a review of our portfolio of product
candidates to determine the future strategy of our programs and the proper allocation of our resources. Following this review, we determined
to discontinue development of our MB-102 (CD123), MB-103 (HER2), MB-104 (CS1) and MB-105 (PSCA) programs and terminated the associated
license agreements. The portfolio of rights licensed from COH now includes patents and applications directed to CARs targeting IL13Rα2,
as well as rights related to modified CAR hinge regions, methods of preparing CAR T cells in particular subpopulations of cells and methods
of administering CAR T cells. The intellectual property licensed thereunder relating to IL13Rα2-targeting CARs includes granted patents
in the U.S., Australia, China, Europe, Russia, Japan, Hong Kong, Israel, and Mexico, and this patent family further includes pending applications
in the U.S., Australia, Brazil, Canada, China, Europe, South Korea, Russia, Japan, Israel, Mexico, and New Zealand. Any patents issuing
from the IL13Rα2-targeting CAR will expire no sooner than 2035. The licensed intellectual property relating to relating modified
CAR hinge regions includes issues patents in China, Europe, and Japan, as well as pending applications in the U.S., Australia, China,
and Europe. The patents issuing from the modified CAR hinge region family will expire no sooner than 2034. The licensed intellectual property
relating to relating to method of preparing or administering CAR T cells includes issues patents in China, Europe, and Japan, as well
as pending applications in the U.S., Australia, Brazil, Canada, China, Europe, Hong